NEW YORK, July 08, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced the appointment of Huw Jones to the newly created role of Vice President, Commercial. Mr. Jones has over 30 years of global experience leading commercial strategy and operations in the pharmaceutical industry, including almost two decades at Novartis Pharmaceuticals and its subsidiaries, most recently at Advanced Accelerator Applications SA and Novartis Oncology, Ltd.
“We are pleased to welcome Huw to our growing commercial operations team to support Progenics’ maturing portfolio of innovative radiopharmaceuticals for the detection and treatment of cancer. He has deep global marketing and sales expertise and, alongside his colleagues in market access and medical affairs, Huw took responsibility for all aspects of the commercial launches of two new radiopharmaceutical products for oncology indications – Lutathera and Netspot® scan. His experience in all phases of commercial launches will be highly valuable to Progenics as we continue to support the launch of AZEDRA and advance our late-stage prostate cancer portfolio,” stated Bryce Tenbarge, Senior Vice President, Commercial, of Progenics.
“I am thrilled to join Progenics and support the Company’s mission of commercializing therapies to find, fight and follow cancer. Progenics has transformed the treatment landscape for pheochromocytoma and paraganglioma with the recent U.S. approval and launch of AZEDRA, and has made significant strides in the ongoing fight against prostate cancer. I look forward to leveraging my commercial experience to accelerate the growth and advancement of the Company’s innovative product portfolio, and I am excited to work alongside the passionate team at Progenics in our shared mission to improve the lives of patients with cancer,” said Mr. Jones.
About Huw Jones
Mr. Jones joins Progenics from Novartis, where he served in multiple commercial leadership positions, most recently as Interim General Manager and Vice President of Marketing and Sales for the company’s subsidiary, Advanced Accelerator Applications SA. In this role, he developed the strategy and oversaw two best-in-class product launches of new radiopharmaceutical products for neuroendocrine tumors (NETs). In his two decades at Novartis and its subsidiaries, Mr. Jones held various global leadership roles, including Executive Director and Global Brand Leader, Head of Global Commercial Excellence, as well as positions of increasing responsibility in general management, sales, marketing, training and commercial operations. Previously, he served in the UK as a Business Unit Head and in sales and marketing management roles at Novo Nordisk Pharmaceuticals and Searle Pharmaceuticals. Mr. Jones earned his Bachelor of Science from Nottingham Trent University.
About PROGENICS
Progenics is an oncology company focused on the development and commercialization of innovative targeted medicines and artificial intelligence to find, fight and follow cancer, including: therapeutic agents designed to treat cancer (AZEDRA®, 1095, and PSMA TTC); prostate-specific membrane antigen (“PSMA”) targeted imaging agent for prostate cancer (PyL™); and imaging analysis technology (aBSI and PSMA AI). Progenics has two commercial products, AZEDRA, for the treatment of patients with unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma (rare neuroendocrine tumors of neural crest origin) who require systemic anticancer therapy; and RELISTOR® (methylnaltrexone bromide) for the treatment of opioid-induced constipation, which is partnered with Bausch Health Companies Inc.
